2022
Guidelines on Germline Testing for Urologic Tumor Syndromes
Gomella P, Mark J, Giri V, Kelly W, Gomella L. Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus 2022, 8: 670-673. PMID: 35803854, DOI: 10.1016/j.euf.2022.06.010.Peer-Reviewed Original ResearchConceptsGermline testingCurrent guidelinesTumor syndromeTreatment of patientsScreening of patientsAvailability of testingDifferent organ systemsGenitourinary cancersGenitourinary tractUrologic cancersTreatment decisionsPatientsOrgan systemsGene mutationsCancerGenetic mutationsSyndromeFamily membersTreatmentGuidelinesMutationsTestingUse of geneticsTract
2021
Adopting Consensus Terms for Testing in Precision Medicine
Martin N, Tepper J, Giri V, Stinchcombe T, Cheng H, Javle M, Konnick E. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precision Oncology 2021, 5: 1563-1567. PMID: 34651094, PMCID: PMC8509918, DOI: 10.1200/po.21.00027.Peer-Reviewed Original ResearchConceptsGenetic testingTreatment decisionsOncology health care providersHealth care providersPrecision medicineLow socioeconomic statusPreferred termPatient advocacy groupsGermline testingTumor characteristicsOncology carePatient preferencesBiomarker testingPatient educationCancer riskCare providersPatient confusionSolid tumorsBlood cancersGermline mutationsGermline variantsAppropriate testingPatientsSocioeconomic statusGenomic testing
2018
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions